Topical imiquimod 5% as an alternative therapy in periocular basal cell carcinoma in two patients with surgical contraindication

Costales-Álvarez, C.; Álvarez-Coronado, M.; Rozas-Reyes, P.; González-Rodríguez, Concepción; Fernández-Vega, Luís

doi:10.1016/j.oftale.2016.11.003

Cited by 3 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…reported two cases one with Alzheimer Disease and the other with acquired immunodeficiency syndrome with encephalopathy and facial dystrophy which were not suitable for surgery and concluded that IMQ was an alternative to surgical treatment in those cases where surgery was not possible. [14] Although surgery is the first-line treatment in these lesions, in case of refusal of surgical treatment, radiotherapy or cryotherapy, when other therapies have failed or are not possible, such as elderly patients, patients requiring long-term care facilities, patients on anticoagulant treatment, patients with either multiple lesions, or superficial diffuse lesions and/or with lesions in regions where reconstruction is difficult, “Treat with the cream first see what's left” policy can be preferred.…”

Section: Discussionmentioning

confidence: 99%

Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area

Karabulut¹,

Kaynak²,

Öztürker³

et al. 2017

Indian J Ophthalmol

View full text Add to dashboard Cite

Context (Background):Imiquimod (IMQ) 5% cream is an immunomodulatory and antitumorigenic agent, which was used as a topical treatment regimen, who had periocular basal cell carcinoma (BCC).Aim:This study aims to present three cases with large BCC at the medial canthal area treated with IMQ 5% cream.Materials and Methods:IMQ 5% cream was used in three patients with ages 45, 49, and 73 who preferred medical treatment over surgery. Following incisional biopsy IMQ cream was used once a day, 5 times a week and the patients were followed up weekly during 12 week treatment period and monthly after the clearance of the lesion.Results:Erythema and erosion on the surface of the lesion, injection of conjunctiva, burning and itching sensation, epiphora and punctate keratitis were seen in all patients during the treatment period. The ophthalmic side effects could be managed by topical lubricating eye drops and the inflammatory reactions resolved within 1 month after cessation of therapy. The patients were followed up for at least 3 years without tumor recurrence and the biopsies taken from the suspected area were found to be tumor free.Conclusion:Surgical excision of carcinoma of the eyelid at medial canthal area can be difficult without causing damage to the lacrimal system and reconstruction of the defect may need grafts or flaps. IMQ may provide an alternative therapy to surgery in certain cases.

show abstract

Section: Discussionmentioning

confidence: 99%

Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area

Karabulut¹,

Kaynak²,

Öztürker³

et al. 2017

Indian J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…En este caso se realizó una división en cuatro grupos principales, como se observa en la tabla 3. (36,56,57,58) AR: alto riesgo; MR: mediano riesgo; BR: bajo riesgo; MAL: metil aminolevulinato; ALA: ácido 5-aminolevulínico.…”

Section: Tratamientosunclassified

Actualización en carcinoma basocelular periocular: abordaje semiológico y diagnóstico diferencial

Nieto¹,

Patiño²,

Estepa³

2019

Cienc. Tecnol. Salud Vis. Ocul.

View full text Add to dashboard Cite

Introducción: este artículo se basa en la revisión y profundización de conceptos actuales rela¬cionados con la semiología clínica y el diagnóstico diferencial, referentes al carcinoma basoce¬lular periocular (CBPO). Objetivo: describir las características semiológicas y los diagnósticos diferenciales del CBPO. Metodología: se realizó una revisión de literatura en las bases de datos ScienceDirect, BVS, Pubmed, SciELO y EBSCO/Medline, mediante los términos MeSH y DeCS “carcinoma”, “basal cell” y “carcinoma basocelular”, con el operador booleano “and” y el término “periocular”, en el periodo 2012-2018. Según el total de estudios relacionados con los términos de la búsqueda, fueron seleccionados artículos escritos en francés, inglés, alemán y español. La calidad de la evidencia científica fue clasificada a través de la metodología de Oxford. Resultados: se describieron las características semiológicas del CBPO y sus diagnósticos diferenciales mediante un flujograma, que permite realizar su identificación clínica. Conclu¬sión: el CBPO es la neoplasia maligna más común del párpado y podría catalogarse, debido a su alta incidencia, como una primera impresión diagnóstica ante la identificación de neoplasias malignas palpebrales. Su detección temprana y el control ante posibles recidivas conforman un objetivo principal del diagnóstico y la prevención en la praxis clínica.

show abstract

“…Demographic information, tumor characteristics, type of management and clinical outcomes of patients treated with periocular IMQ have been summarized (Table 1). [1][2][3][4][5][6][7][8][9] A total of 175 patients was reported (109 males, 61 females, 5 not specified 3 ) with a mean age of 71.27 years old (range 9-95 years). Overall, 180 periocular lesions treated with IMQ have been counted: 106 BCCs, 41 AK, 20 MIS, 11 Bowen's diseases, and 2 cSCCs.…”

mentioning

confidence: 99%

Imiquimod‐side effects in the treatment of periocular skin cancers: A review of the literature

Avallone

Merli

Dell’Aquila

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Topical imiquimod 5% as an alternative therapy in periocular basal cell carcinoma in two patients with surgical contraindication

Cited by 3 publications

References 9 publications

Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area

Imiquimod 5% cream for the treatment of large nodular basal cell carcinoma at the medial canthal area

Actualización en carcinoma basocelular periocular: abordaje semiológico y diagnóstico diferencial

Imiquimod‐side effects in the treatment of periocular skin cancers: A review of the literature

Contact Info

Product

Resources

About